{"transactions":[{"id":1679722,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2024-01-13T02:55:09.000Z","date":"2024-01-10","kind":"sale","planned":false,"acquired":false,"shares":1050000,"price":18,"value":18900000.0,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4400000,"source":{"system":"sec-edgar","filing":"0001493152-24-002290","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000149315224002290/ownership.xml","form_type":"4"}},{"id":1763420,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche 2 Warrants (Right to Buy)","published_at":"2023-10-06T20:05:25.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":1690014,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 4, 2023, Vistagen Therapeutics, Inc. (the \"Issuer\") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share (\"Common Stock\") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the \"Tranche 1 Warrants\") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the \"Tranche 2 Warrants\"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the \"Pre-Funded Warrants\") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP (\"Commodore Capital\") is no longer a 10% beneficial owner of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Tranche 2 Warrants are exercisable from the date of issuance and expire on October 4, 2028. The Tranche 2 Warrants contain an exercise limitation prohibiting Commodore Master from exercising the Tranche 2 Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Tranche 2 Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1690014,"derivative":{"exercise_price":8.877,"exercise_date":"2023-10-04","expiration_date":"2028-10-04","underlying":"Common Stock","underlying_shares":1690014},"source":{"system":"sec-edgar","filing":"0001493152-23-036497","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000149315223036497/ownership.xml","form_type":"4"}},{"id":1763419,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Tranche 1 Warrants (Right to Buy)","published_at":"2023-10-06T20:05:25.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":1394310,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 4, 2023, Vistagen Therapeutics, Inc. (the \"Issuer\") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share (\"Common Stock\") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the \"Tranche 1 Warrants\") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the \"Tranche 2 Warrants\"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the \"Pre-Funded Warrants\") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP (\"Commodore Capital\") is no longer a 10% beneficial owner of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Tranche 1 Warrants are exercisable from the date of issuance and expire 60 days after the later of (i) the date on which the Issuer first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-3 study and (ii) the date on which the Issuer first publicly discloses, whether by press release or Form 8-K filing, the top-line data for its PALISADE-4 study. The Tranche 1 Warrants contain an exercise limitation prohibiting Commodore Master from exercising the Tranche 1 Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Tranche 1 Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1394310,"derivative":{"exercise_price":5.38,"exercise_date":"2023-10-04","underlying":"Common Stock","underlying_shares":1394310},"source":{"system":"sec-edgar","filing":"0001493152-23-036497","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000149315223036497/ownership.xml","form_type":"4"}},{"id":1763418,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2023-10-06T20:05:25.000Z","date":"2023-10-04","kind":"grant","planned":false,"acquired":true,"shares":2788620,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 4, 2023, Vistagen Therapeutics, Inc. (the \"Issuer\") closed an offering of 15,010,810 shares of its common stock, $0.001 par value per share (\"Common Stock\") with accompanying common warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the \"Tranche 1 Warrants\") and accompanying common warrants to purchase up to 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the \"Tranche 2 Warrants\"). In lieu of shares of Common Stock, the Issuer offered pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the \"Pre-Funded Warrants\") with accompanying Tranche 1 Warrants and accompanying Tranche 2 Warrants. As a result of the offering and certain ownership limitations described below, Commodore Capital LP (\"Commodore Capital\") is no longer a 10% beneficial owner of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer offered Pre-Funded Warrants at a combined offering price of $5.379 per Pre-Funded Warrant, accompanying Tranche 1 Warrant, and accompanying Tranche 2 Warrant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable from the date of issuance until fully exercised. The Pre-funded Warrants contain an exercise limitation prohibiting Commodore Capital Master LP (\"Commodore Master\") from exercising the Pre-Funded Warrants until such time as the holder, together with certain related parties, would not beneficially own after any such exercise more than 9.99% of the then issued and outstanding Common Stock. Due to this blocker, the Pre-funded Warrants owned by Commodore Master are not fully exercisable at this time. The blocker percentage may be increased up to 19.99% or decreased by Commodore Master upon 61 days' notice to the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held directly by Commodore Master. Commodore Capital is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2788620,"derivative":{"exercise_price":0.001,"exercise_date":"2023-10-04","underlying":"Common Stock","underlying_shares":2788620},"source":{"system":"sec-edgar","filing":"0001493152-23-036497","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000149315223036497/ownership.xml","form_type":"4"}},{"id":1811892,"issuer":{"id":7955,"kind":"organization","name":"Vistagen Therapeutics, Inc."},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-08-09T20:10:18.000Z","date":"2023-08-07","kind":"purchase","planned":false,"acquired":true,"shares":775756,"price":23.153,"value":17961078.668,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.00 to $25.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1575000,"source":{"system":"sec-edgar","filing":"0001493152-23-027352","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1411685/000149315223027352/ownership.xml","form_type":"4"}},{"id":1846051,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-06-22T20:10:17.000Z","date":"2023-06-20","kind":"purchase","planned":false,"acquired":true,"shares":448217,"price":15.169,"value":6799003.673,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.89 to $15.1904 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":5450000,"source":{"system":"sec-edgar","filing":"0001493152-23-022130","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000149315223022130/ownership.xml","form_type":"4"}},{"id":1990378,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, par value $0.001 per share","published_at":"2023-02-27T22:14:19.000Z","date":"2023-02-23","kind":"other","acquired":true,"shares":729891,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 23, 2023, IMARA Inc. (\"IMARA\") completed a merger with Enliven Therapeutics, Inc. (\"Legacy Enliven\"), with Legacy Enliven surviving the merger as a direct wholly owned subsidiary of IMARA (the \"Merger\"). Prior to the Merger, the Reporting Person was a shareholder of both IMARA and Legacy Enliven. At the effective time of the Merger, the Reporting Person's 2,473,327 shares in Legacy Enliven converted into 729,891 shares of IMARA's Common Stock. In connection with the Merger, the Reporting Person also received a dividend of one Contingent Value Right (\"CVR\") for or each outstanding share of IMARA's Common Stock held on February 22, 2023. Accordingly, the Reporting Person received 2,872,513 CVRs, each representing the right to receive contingent payments upon the occurrence of certain events, as set forth in the Contingent Value Rights Agreement. As a result of the Merger, the Reporting Person is no longer a 10% owner of the Issuer as of the date of this Form 4."},{"field":"shares","element":"transactionShares","label":"F3","text":"On February 23, 2023, IMARA Inc. (\"IMARA\") completed a merger with Enliven Therapeutics, Inc. (\"Legacy Enliven\"), with Legacy Enliven surviving the merger as a direct wholly owned subsidiary of IMARA (the \"Merger\"). Prior to the Merger, the Reporting Person was a shareholder of both IMARA and Legacy Enliven. At the effective time of the Merger, the Reporting Person's 2,473,327 shares in Legacy Enliven converted into 729,891 shares of IMARA's Common Stock. In connection with the Merger, the Reporting Person also received a dividend of one Contingent Value Right (\"CVR\") for or each outstanding share of IMARA's Common Stock held on February 22, 2023. Accordingly, the Reporting Person received 2,872,513 CVRs, each representing the right to receive contingent payments upon the occurrence of certain events, as set forth in the Contingent Value Rights Agreement. As a result of the Merger, the Reporting Person is no longer a 10% owner of the Issuer as of the date of this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 23, 2023, IMARA Inc. (\"IMARA\") completed a merger with Enliven Therapeutics, Inc. (\"Legacy Enliven\"), with Legacy Enliven surviving the merger as a direct wholly owned subsidiary of IMARA (the \"Merger\"). Prior to the Merger, the Reporting Person was a shareholder of both IMARA and Legacy Enliven. At the effective time of the Merger, the Reporting Person's 2,473,327 shares in Legacy Enliven converted into 729,891 shares of IMARA's Common Stock. In connection with the Merger, the Reporting Person also received a dividend of one Contingent Value Right (\"CVR\") for or each outstanding share of IMARA's Common Stock held on February 22, 2023. Accordingly, the Reporting Person received 2,872,513 CVRs, each representing the right to receive contingent payments upon the occurrence of certain events, as set forth in the Contingent Value Rights Agreement. As a result of the Merger, the Reporting Person is no longer a 10% owner of the Issuer as of the date of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1448640,"source":{"system":"sec-edgar","filing":"0001493152-23-006118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000149315223006118/ownership.xml","form_type":"4"}},{"id":1990377,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, par value $0.001 per share","published_at":"2023-02-27T22:14:19.000Z","date":"2023-02-23","kind":"purchase","acquired":true,"shares":621.75,"price":22.072,"value":13723.266,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.72 to $25.28 per share, inclusive, prior to the consummation of the Merger (as defined below). The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":718749,"source":{"system":"sec-edgar","filing":"0001493152-23-006118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000149315223006118/ownership.xml","form_type":"4"}},{"id":1995974,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, par value $0.001 per share","published_at":"2023-02-23T21:05:36.000Z","date":"2023-02-22","kind":"purchase","acquired":true,"shares":23565,"price":5.113,"value":120487.845,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.45 to $5.64 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2872513,"source":{"system":"sec-edgar","filing":"0001493152-23-005870","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000149315223005870/ownership.xml","form_type":"4"}},{"id":1995973,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, par value $0.001 per share","published_at":"2023-02-23T21:05:36.000Z","date":"2023-02-21","kind":"purchase","acquired":true,"shares":8194,"price":5.249,"value":43010.306,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.18 to $5.37 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2848948,"source":{"system":"sec-edgar","filing":"0001493152-23-005870","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000149315223005870/ownership.xml","form_type":"4"}},{"id":2114581,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2022-11-16T16:05:51.000Z","date":"2022-11-14","kind":"sale","acquired":false,"shares":3250000,"price":0.706,"value":2294500.0,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.596 to $0.7997 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":461286,"source":{"system":"sec-edgar","filing":"0001493152-22-032622","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000149315222032622/ownership.xml","form_type":"4"}},{"id":2493293,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-11-29T16:30:55.000Z","date":"2021-11-24","kind":"purchase","acquired":true,"shares":2922,"price":5.42,"value":15837.24,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.37 to $5.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3711286,"source":{"system":"sec-edgar","filing":"0000905718-21-001545","document":"satsuma_fm4nov242021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001545/satsuma_fm4nov242021.xml","form_type":"4"}},{"id":2498296,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-11-23T16:30:54.000Z","date":"2021-11-22","kind":"purchase","acquired":true,"shares":9979,"price":5.49,"value":54784.71,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.43 to $5.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3708364,"source":{"system":"sec-edgar","filing":"0000905718-21-001523","document":"satsuma_fm4nov192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001523/satsuma_fm4nov192021.xml","form_type":"4"}},{"id":2498295,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-11-23T16:30:54.000Z","date":"2021-11-19","kind":"purchase","acquired":true,"shares":3225,"price":5.44,"value":17544.0,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.38 to $5.58 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3698385,"source":{"system":"sec-edgar","filing":"0000905718-21-001523","document":"satsuma_fm4nov192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001523/satsuma_fm4nov192021.xml","form_type":"4"}},{"id":2515153,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-11-12T16:31:21.000Z","date":"2021-11-11","kind":"purchase","acquired":true,"shares":7941,"price":6.05,"value":48043.05,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.95 to $6.10 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3695160,"source":{"system":"sec-edgar","filing":"0000905718-21-001471","document":"satsuma_fm4nov102021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001471/satsuma_fm4nov102021.xml","form_type":"4"}},{"id":2515152,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-11-12T16:31:21.000Z","date":"2021-11-10","kind":"purchase","acquired":true,"shares":9622,"price":5.85,"value":56288.7,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.83 to $5.89 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3687219,"source":{"system":"sec-edgar","filing":"0000905718-21-001471","document":"satsuma_fm4nov102021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001471/satsuma_fm4nov102021.xml","form_type":"4"}},{"id":2517846,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-11-10T16:30:25.000Z","date":"2021-11-08","kind":"purchase","acquired":true,"shares":560,"price":5.99,"value":3354.4,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.98 to $6.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3677597,"source":{"system":"sec-edgar","filing":"0000905718-21-001460","document":"satsuma_fm4nov82021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001460/satsuma_fm4nov82021.xml","form_type":"4"}},{"id":2521482,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-11-08T16:33:50.000Z","date":"2021-11-05","kind":"purchase","acquired":true,"shares":7800,"price":5.95,"value":46410.0,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.91 to $5.99 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3677037,"source":{"system":"sec-edgar","filing":"0000905718-21-001450","document":"satsuma_fm4nov42021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001450/satsuma_fm4nov42021.xml","form_type":"4"}},{"id":2521481,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-11-08T16:33:50.000Z","date":"2021-11-04","kind":"purchase","acquired":true,"shares":1400,"price":5.88,"value":8232.0,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.90 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3669237,"source":{"system":"sec-edgar","filing":"0000905718-21-001450","document":"satsuma_fm4nov42021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001450/satsuma_fm4nov42021.xml","form_type":"4"}},{"id":2524574,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-11-04T16:31:23.000Z","date":"2021-11-02","kind":"purchase","acquired":true,"shares":8880,"price":5.64,"value":50083.2,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.48 to $5.70 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3667837,"source":{"system":"sec-edgar","filing":"0000905718-21-001430","document":"satsuma_fm4nov22021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001430/satsuma_fm4nov22021.xml","form_type":"4"}},{"id":2528980,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-11-02T16:30:45.000Z","date":"2021-10-29","kind":"purchase","acquired":true,"shares":44651,"price":5.71,"value":254957.21,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.49 to $5.80 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3658957,"source":{"system":"sec-edgar","filing":"0000905718-21-001420","document":"satsuma_fm4oct292021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001420/satsuma_fm4oct292021.xml","form_type":"4"}},{"id":2531888,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-10-29T16:30:22.000Z","date":"2021-10-28","kind":"purchase","acquired":true,"shares":15082,"price":5.55,"value":83705.1,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.45 to $5.60 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3614306,"source":{"system":"sec-edgar","filing":"0000905718-21-001408","document":"satsuma_fm4oct272021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001408/satsuma_fm4oct272021.xml","form_type":"4"}},{"id":2531887,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-10-29T16:30:22.000Z","date":"2021-10-27","kind":"purchase","acquired":true,"shares":39581,"price":5.45,"value":215716.45,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.34 to $5.55 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3599224,"source":{"system":"sec-edgar","filing":"0000905718-21-001408","document":"satsuma_fm4oct272021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001408/satsuma_fm4oct272021.xml","form_type":"4"}},{"id":2535568,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-10-25T16:31:10.000Z","date":"2021-10-22","kind":"purchase","acquired":true,"shares":27629,"price":5.51,"value":152235.79,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.42 to $5.60 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3559643,"source":{"system":"sec-edgar","filing":"0000905718-21-001391","document":"satsuma_fm4212021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001391/satsuma_fm4212021.xml","form_type":"4"}},{"id":2535567,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-10-25T16:31:10.000Z","date":"2021-10-21","kind":"purchase","acquired":true,"shares":32816,"price":5.4,"value":177206.4,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.32 to $5.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3532014,"source":{"system":"sec-edgar","filing":"0000905718-21-001391","document":"satsuma_fm4212021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001391/satsuma_fm4212021.xml","form_type":"4"}},{"id":2537358,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-10-21T16:30:58.000Z","date":"2021-10-20","kind":"purchase","acquired":true,"shares":40663,"price":5.44,"value":221206.72,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.28 to $5.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3499198,"source":{"system":"sec-edgar","filing":"0000905718-21-001384","document":"satsuma_fm4oct192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001384/satsuma_fm4oct192021.xml","form_type":"4"}},{"id":2537357,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-10-21T16:30:58.000Z","date":"2021-10-19","kind":"purchase","acquired":true,"shares":87580,"price":5.07,"value":444030.6,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.99 to $5.10 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3458535,"source":{"system":"sec-edgar","filing":"0000905718-21-001384","document":"satsuma_fm4oct192021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001384/satsuma_fm4oct192021.xml","form_type":"4"}},{"id":2539373,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-10-19T17:13:59.000Z","date":"2021-10-18","kind":"purchase","acquired":true,"shares":36194,"price":4.87,"value":176264.78,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.84 to $4.98 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3370955,"source":{"system":"sec-edgar","filing":"0000905718-21-001373","document":"satsumapharm_fm4oct152021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001373/satsumapharm_fm4oct152021.xml","form_type":"4"}},{"id":2539372,"issuer":{"id":112442,"kind":"organization","name":"Satsuma Pharmaceuticals, Inc.","symbol":"STSA"},"owners":[{"id":95219,"kind":"organization","name":"Commodore Capital LP","position":1,"cik":"0001831942","reported_name":"COMMODORE CAPITAL LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2021-10-19T17:13:59.000Z","date":"2021-10-15","kind":"purchase","acquired":true,"shares":126000,"price":4.83,"value":608580.0,"ownership":{"direct":false,"nature":"By Commodore Capital Master LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.75 to $4.90 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Commodore Capital Master LP (\"Commodore Master\"). Commodore Capital LP (\"Commodore Capital\") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Mr. Kramarz and Mr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Mr. Kramarz and Mr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3334761,"source":{"system":"sec-edgar","filing":"0000905718-21-001373","document":"satsumapharm_fm4oct152021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1692830/000090571821001373/satsumapharm_fm4oct152021.xml","form_type":"4"}}]}